Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
22 Octobre 2024 - 10:05PM
Business Wire
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for patients with cancer,
announced that its management team will host a conference call and
webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to
discuss details of the Company’s financial results and pipeline
update for the quarter ended September 30th, 2024.
Investors interested in listening to the conference call may do
so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428
(toll-free), using Access Code: 940081. Participants may also
register for the call online using the following link:
https://www.netroadshow.com/events/login?show=4818aee3&confId=72838.
To access the live webcast and accompanying slide presentation,
please visit the “Investors & Media” section of the Arcus
Biosciences website at www.arcusbio.com. A replay of the webcast
will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for patients with cancer. In partnership with industry
collaborators, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b
receptor, CD39, and AXL. For more information about Arcus
Biosciences’ clinical and preclinical programs, please visit
www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241022900050/en/
Investor Inquiries Pia Eaves VP of Investor Relations
& Strategy (617) 459-2006 peaves@arcusbio.com
Media Inquiries Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Arcus Biosciences (NYSE:RCUS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
